Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVSVΔG-ZEBOV-GP Ebola vaccine trial in healthy children and relatives in Lambaréné
PACTR202005733552021Phase 2Completed
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- Jan 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoints: rVSV concentration in blood, urine, or saliva, Solicited local adverse events and 4 more. Started Jan 2021; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202005733552021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202005733552021.